OCUMETICS TECHNOLOGY CORP Aktie

Calgary, Alberta – TheNewswire - May 14, 2025 - Ocumetics Technology Corp . (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce it has successfully manufactured its inaugural accommodating intraocular lenses (the “Ocumetics Lens”) for use in its upcoming first-in-human (FIH) clinical study planned for summer 2025. Each Ocumetics Lens produced has demonstrated, using the IOLA lens analyzer, consistent quality and precision in alignment with study requirements and stringent clinical standards.   Dean Burns, President and CEO of Ocumetics, stated: “Our international design teams have worked diligently to refine and validate our production protocols. I'm confident that the manufacturing processes developed by our team will deliver the consistency in lens quality that is not only essential for clinical trial success but also vital to Ocumetics' long-term vision of commercial scalability. This is a proud moment for the team as we prepare to deliver a transformative technology into clinical use.”» Mehr auf thenewswire.com

Calgary, Alberta – TheNewswire - May 12 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the successful completion of its optimized lens prototype design. With this milestone, Ocumetics has formally initiated a design freeze - locking in lens specifications that will be used in its upcoming first-in-human (FIH) clinical study planned for summer 2025. Dean Burns, CEO of Ocumetics, stated: “This is a defining milestone for Ocumetics.  This optimized lens design reflects our commitment to precision, performance, and patient safety. With the design now locked, we can advance with the manufacturing and regulatory processes leading up to our first-in-human studies planned for this summer. With each completed step the path to delivering a transformative solution for vision correction is clearer than ever.”» Mehr auf thenewswire.com

Calgary, Alberta – TheNewswire - May 8, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce a significant breakthrough in its development of next-generation intraocular lens technology. In recent laboratory testing, the Company successfully demonstrated accommodative power change using 3D-printed moulded lenses under simulated ciliary body compression conditions - marking a pivotal step forward in the pursuit of restoring youthful vision.  Accommodative power refers to the eye's ability to focus between near and far distances following lens replacement surgery.   Dean Burns, CEO of Ocumetics, stated: “These results represent a critical milestone for Ocumetics and for the future of ophthalmology. The data supports our confidence in the platform and strengthens our commitment to delivering a lens that not only corrects vision but restores the natural focusing ability lost with age. Our next steps will continue to focus on preparing for our first-in-human studies, planned for summer 2025.”» Mehr auf thenewswire.com